Gastric acid secretion inhibiting composition
First Claim
1. An oral pharmaceutical dosage form comprising pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof and an H2 receptor antagonist or a salt thereof, and a pharmaceutically acceptable carrier, wherein the acid susceptible proton pump inhibitor or a salt thereof is separated from the H2 receptor antagonist by an enteric coating.
1 Assignment
0 Petitions
Accused Products
Abstract
An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a pharmaceutically acceptable carrier. The dosage form is capable of raising gastric pH to above 4 within two hours after administration and to keep it at that level for at least 4 hours. Also disclosed is a method of manufacture of the dosage form, its use in treating dyspepsia and infection by Helicobacter pylori, and a method of treating disorders associated with gastric acid secretion.
-
Citations
38 Claims
- 1. An oral pharmaceutical dosage form comprising pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof and an H2 receptor antagonist or a salt thereof, and a pharmaceutically acceptable carrier, wherein the acid susceptible proton pump inhibitor or a salt thereof is separated from the H2 receptor antagonist by an enteric coating.
- 23. A method for the manufacture of an oral tableted dosage form comprising amounts of an acid susceptible proton pump inhibitor or salt thereof and an H2 receptor antagonist or salt thereof pharmacologically effective in treating a condition related to dyspepsia, the method comprising forming a first layer comprising said acid susceptible proton pump inhibitor or salt thereof, an enteric coat surrounding said first layer, and a second layer comprising said H2 receptor antagonist or salt thereof surrounding said first layer and said enteric coat.
- 24. A method for the manufacture of an oral dosage form comprising amounts of an acid susceptible proton pump inhibitor or salt thereof and an H2 receptor antagonist or salt thereof pharmacologically effective in treating a condition related to dyspepsia, the method comprising forming pellets comprising said acid susceptible proton pump inhibitor or salt thereof, covering said pellets with enteric coat, and mixing said pellets covered with said enteric coat with a carrier comprising said H2 receptor antagonist or salt thereof.
Specification